American Association for Cancer Research
Browse
15357163mct080939-sup-mct-08-0939--suppl_fig_1.pdf (94.47 kB)

Supplementary Fig. S1 from The antitumoral effect of Paris Saponin I associated with the induction of apoptosis through the mitochondrial pathway

Download (94.47 kB)
journal contribution
posted on 2023-03-31, 23:20 authored by Xue Xiao, Peng Bai, Tri M. Bui Nguyen, Jianguo Xiao, Shanling Liu, Gong Yang, Lina Hu, Xinlian Chen, Xuemei Zhang, Jinsong Liu, He Wang
Supplementary Fig. S1 from The antitumoral effect of Paris Saponin I associated with the induction of apoptosis through the mitochondrial pathway

History

ARTICLE ABSTRACT

Rhizoma Paridis, a traditional Chinese medicine, has shown promise in cancer prevention and therapy. In the present study, we isolated Paris Saponin I (PSI), an active component of Rhizoma paridis, and evaluated its effects on a panel of human cell lines and in a mouse model of human ovarian cancer to explore the mechanisms of its activity. PSI had more potent and selective cytotoxic effects on tumor cell lines than etoposide had, promoting dramatic G2-M phase arrest and apoptosis in SKOV3 cells in a time- and dose-dependent manner. Furthermore, PSI treatment increased levels of Bax, cytochrome c, activated caspase-3, active caspase-9, and cleaved poly(ADP-ribose) polymerase and decreased both Bcl-2 expression levels and extracellular signal–regulated kinase-1/2 activity. We also assessed the antitumor efficacy of i.p. and p.o. PSI administration in mice bearing SKOV3 tumors; both significantly inhibited the growth of SKOV3 cells in a subcutaneous xenograft mouse model (by 66% and 52%, respectively). These results indicate that PSI mediates its effects via mitochondrial apoptosis, mitogen-activated protein kinase pathways, and G2-M cell cycle arrest. Most important, the efficacy of PSI in xenografts when administered p.o. or i.p. suggests its clinical potential. Thus, PSI is a potent antitumor compound and should be developed as a natural agent for cancer therapy.[Mol Cancer Ther 2009;8(5):1179–88]

Usage metrics

    Molecular Cancer Therapeutics

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC